Related Experiment Video
Updated: Jun 3, 2026
11:17
Rapid Point-of-Care Assay of Enoxaparin Anticoagulant Efficacy in Whole Blood
Published on: October 12, 2012
Low molecular weight heparins differ substantially: impact on developing biosimilar drugs.
Jeanine M Walenga1, Craig M Jackson, Craig M Kessler
1Cardiovascular Institute, Loyola University Medical Center, Maywood, Illinois 60153, USA. jwaleng@lumc.edu
Seminars in Thrombosis and Hemostasis
|April 2, 2011
Summary
Developing biosimilar low molecular weight heparins (LMWHs) presents unique challenges due to their complex structure. Ensuring the safety and efficacy of these generic biologic medicines is crucial for patient care and healthcare reform.
Area of Science:
- Pharmacology and Drug Development
- Biologics and Biosimilars
- Health Policy
Background:
- Generic drugs are key to healthcare reform, but biosimilars require stringent safety and efficacy evaluations.
- Low molecular weight heparins (LMWHs) are vital for treating venous thromboembolism.
- The complex nature of LMWHs complicates the development of generic versions (biosimilars).
Purpose of the Study:
- To highlight the challenges in developing biosimilar LMWHs.
- To discuss the implications of product variability for patient safety and effectiveness.
- To recommend improvements for pending U.S. legislation on biosimilars.
Main Methods:
- Review of current scientific understanding of LMWH complexity.
- Analysis of expert body recommendations on biosimilar LMWH development.
- Evaluation of existing and proposed legislative frameworks for biosimilars.
Main Results:
- Biosimilar LMWH production faces significant hurdles compared to small molecule generics.
- Product variability can lead to critical differences in potency, safety, and immune responses.
- Existing legislation may not adequately address the unique risks of biosimilar LMWHs.
Conclusions:
- Biosimilar LMWH development requires specialized considerations beyond current generic drug regulations.
- Recommendations are provided to enhance legislative oversight for biosimilar LMWHs.
- Prioritizing patient safety is paramount in the integration of biosimilar LMWHs into clinical practice.
More Related Videos
Related Concept Videos
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
01:28Drug Products: Biologics, Biosimilars and Interchangeables
Biologics, derived from living sources such as humans, animals, or microorganisms, represent a significant category of pharmaceuticals. These complex molecules, developed through advanced biotechnological methods or purified from natural sources, include essential medical treatments like insulin and growth hormones. The complexity of biologics arises from their large molecular structures and the intricate processes required for their production, making them distinct from conventional...
01:27Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
01:16Bioequivalence: Overview
Pharmaceutical equivalents, by definition, are drug products with the same active ingredient in the same quantities, encapsulated in identical dosage forms, and intended for the same administration routes. These pharmaceutical equivalents are deemed bioequivalent if the bioavailability of the active entity in the drug preparations is similar. Moreover, pharmaceutical equivalents demonstrating bioequivalence are also regarded as therapeutically equivalent. This means that when used as directed,...
01:13Bioequivalence studies: Biowaivers
In certain scenarios, in vitro dissolution tests can replace in vivo bioequivalence studies. This is particularly true when a drug product, though available in varying strengths, maintains proportional similarity in its active and inactive ingredients. In such cases, the need for in vivo bioequivalence studies for lower strength variants may be waived, provided dissolution tests and in vivo studies on the highest strength yield satisfactory results.Bioequivalence can be indicated through...
01:22Pharmaceutical Alternatives: Stability-Related Therapeutic Nonequivalence
Generic intravenous (IV) drugs are considered bioequivalent to their branded counterparts due to their 100% bioavailability upon administration. However, variations in stability among different drug products can significantly influence their therapeutic performance, even if they are pharmaceutically equivalent.Cefuroxime, a prophylactic antimicrobial, is often used as a single-dose IV injection for patients undergoing coronary artery bypass grafting surgery. A 3 g dose typically provides...